Previous close | 0.9200 |
Open | 1.2000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 41.00 |
Expiry date | 2024-06-21 |
Day's range | 0.8800 - 1.3000 |
Contract range | N/A |
Volume | |
Open interest | 3.28k |
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.